Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib plus Letrozole in Metastatic Breast Cancer
NCT00696072Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2008
- Primary completion
- Jun 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in breast cancer, sponsored by Bristol Myers Squibb. Started Aug 2008; status: completed.
02
Drugs
dasatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00696072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00696072.